Vorträge/Posterpräsentationen:

2019

181. Deters MA, Obarcanin E, Schwender H, Läer S. Proof of Concept Studie EMDIA – effektives Medikationsmanagement für Patienten mit Diabetes mellitus Typ 2, Aachen (2019) Poster und Vortrag

https://www.mmp-online.de/heftarchiv/2019/11/arzneimittelsicherheit-in-der-paediatrie-und-telemedizin-abstracts-der-poster-vorgestellt-bei-der-jahrestagung-der-deutschen-gesellschaft-fuer-klinische-pharmazie-am-22-und-23-november-2019-in-aachen.html

180. Ali M, Tins J, Burckhardt BB. Establishing the integrity of the continuous paediatric pharmacokinetic bioanalysis for clinical trial within an academia environment using quality assessment process. ESDPPP Congress Basel, Switzerland (2019)

179. Ali M, Läer S, Burckhardt BB. LC-MS/MS method for screening of intoxication and drug adherence of angiotensin converting enzyme inhibitors in plasma. Mass Spectrometry Application in Clinical Lab (MSACL), Salzburg, Austria (2019)

178. Feickert M, Burckhardt BB. Design of experiments as a key element for enabling the endogenous mass spectrometric determination of Substance P and related Hemokinin-1, Euroanalysis Istanbul, Turkey (2019), Oral presentation OP-009, p.136

177. Feickert M, Burckhardt BB. A quality-controlled and design of experiments-based approach for the optimization of the chromatographic solvent composition for the determination of Substance P and Hemokinin-1, HPLC Milan, Italy (2019), PP-376

176. Feickert M, Burdman I, Makowski N, Ali M, Farahani S, Majid H, Ciplea AM, Bartel A, Burckhardt BB. Reliable results in continuous bioanalysis of paediatric renin samples – comprehensive quality assessment within clinical studies in children, ESDPPP Congress Basel, Switzerland (2019), P34

https://doi.org/10.1136/archdischild-2019-esdppp.72

175. Feickert M, Burckhardt BB. Aprepitant in the prevention of cardiotoxic adverse effects of Doxorubicin in the paediatric population - a systematic literature investigation. ESDPPP Congress Basel, Switzerland (2019), P35

https://doi.org/10.1136/archdischild-2019-esdppp.73

174. Farahani I, Laven A, Farahani S, Deters MA, Feickert M, Süßenbach FK, Schwender H, Läer S. Effectiveness of OSCEs in training German pharmacy students in consultation on self-medication - a randomised controlled investigation. ESDPPP Congress Basel, Switzerland (2019), P33

173. Gangnus T, Süßenbach FK, Makowski N, Burdman I, Läer S, Burckhardt BB. Reference ranges of blood NT-proBNP in paediatric heart failure and healthy controls: compilation of literature data. ESDPPP Basel, Switzerland (2019), Poster P37, Archives of Disease in Childhood 2019;104:e32

172. Gangnus T, Burckhardt BB. Mobile phase optimization applying a design of experiments approach to increase the signal response in LC-MS/MS of bradykinin and its internal standard. HPLC Milan, Italy (2019), Poster 291

171. Gangnus T, Burckhardt BB. A lean approach to examine surface adsorption of the low-abundant peptide bradykinin and to increase its signal intensity in LC-MS/MS: a design of experiments concept. Euroanalysis Istanbul, Turkey (2019), Poster PP2-041; Poster 041: 3. Platz beim Springer Poster Pitch Presentations Award

170. Farahani S, Feles E, Burckhardt BB, Läer S on behalf of the LENA consortium. Depiction of haematological and biochemical laboratory normal reference values in a European multicentre paediatric trial. ESDPPP Congress Basel, Schwitzerland (2019), P32

169. Deters MA, Obarcanin E, Schwender H, Läer S. Assessment of selected pharmaceutical care components for coaching community pharmacists in medication therapy management (MTM) for patients with diabetes. ESCP Congress Ljubljana, Slovenia (2019), Poster CP-PC021

168. Deters MA, Laven A, Castejon AM, Doucette WR, Ev LS, Krass I, Mehuys E, Obarcanin E, Schwender H, Läer S. A meta-analysis of pharmaceutical care components for diabetes patients. DDG Kongress Berlin (2019), Poster EP30

https://events.mcon-mannheim.de/frontend/index.php?page_id=4279&v=AuthorList&do=17&day=180&entity_id=124647

167. Faisal M, Cawello W, Läer S. Simultaneous population pharmacokinetic analysis of enalapril in serum and urine administered using orodispersible mini-tablets for use in children. ASCPT Washington, USA, Poster Session (PIII-042), Clinical Pharmacology and Therapeutics (2019) 105(S1), p S94

https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1344

2018

166. Makowski N, Süßenbach FK, Burckhardt BB. A novel GCLP-compliant bioanalytical LC-HRMS method for the reliable determination of aldosterone, precursor and metabolite facilitating further insight into paediatric maturation of the renin-angiotensin-aldosterone-system. DPhG Jahrestagung 2018, Hamburg, Tagungsband (2018) POS. 100, p. 134

https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf

165. Burdman I, Burckhardt BB. Appraisal of immunocapture by different antibodies prior to a surrogate peptide approach utilizing LC-HRMS analysis for quantification of the low abundant protein renin in human plasma. DPhG Jahrestagung 2018, Hamburg, Tagungsband (2018) POS. 100, p. 134

https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf

164. Majid H, Kottke D, Bartel A, Burckhardt BB. Approach of a physiologically-based permeation model utilizing LC-MS/MS to investigate the Safety Potential of Buccal Drug Applications. DPhG Jahrestagung 2018, Hamburg, Tagungsband (2018) POS. 162, pp. 164 - 165

https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf

163. Süßenbach FK, Makowski N, Burckhardt BB. Evaluation of RAAS peptides in complex biological matrices in paediatric patients: Development and validation of a low-volume LC-HRMS Method. DPhG Jahrestagung 2018, Hamburg, Tagungsband (2018) POS. 121, p. 144 sowie Poster session (PI 121), Tagungsband (2018) POS. 121, p. 144

https://www.dphg.de/fileadmin/downloads/DPhG2018_ConferenceBook_Final_27-09-2018.pdf

162. Kottke D, Majid H, Breitkreutz J, Burckhardt BB. Ex vivo permeation studies to facilitate the development of a buccal child-appropriate dosage form by using lidocaine. BioBarriers 2018, Saarbrücken, POS. 165, p. 113

http://biobarriers.hips-wordpress.helmholtz-hzi.de/wp-content/uploads/sites/2/2017/07/BB18-Book-of-Abstracts.pdf

161. Faisal M, Cawello W, Läer S. Pharmacokinetic comparison of enalapril administered using market authorized and child appropriate dosage formulations. ACCP Seattle, USA; Pharmacometrics NRW, Köln, Poster Sessions; JACCP (2018) 1(2), p. 265, Poster (382)

https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/jac5.1059

160. Burckhardt BB, Ciplea AM, Laven A, Kleine K, Ablonczy L, Breur JMPJ, Dalinghaus M, van der Meulen M, Klingmann I, Spatenkova L, Swoboda V, Bajcetic M, Keatley-Clark A, Läer S, Lagler FB. Tailored simulation training as an innovative Training concept to facilitate successful study conduct and recruitment encompassing its assessment. ASCPT Orlando, USA, Kongressbeitrag

2017

159. Burckhardt, B.B.; Laven, A.; Kleine, K.; Ablonczy, L.; Breur, JMPJ; Dalinghaus, M.; van der Meulen, M.; Klingmann, I.; Spatenkova L.; Swoboda, V.; Bajcetic, M.; Keatley-Clark, A.; Läer, S.; Lagler, F.B. Innovative training concept to overcome main reasons for failed pediatric clinical trials and to facilitate successful study conduct and recruitment. Annual conference of the American Heart Association, Anaheim (November 2017)

158. Deters MA, Laven A, Castejon AM, Doucette WR, Ev LS, Krass I, Mehuys E, Obarcanin E, Schwender H, Läer S. Effective interventions for diabetes patients by community pharmacists – a meta-analysis of pharmaceutical care components. ESCP, Heidelberg, All Accepted Abstracts, p. 68, Poster CP-PC024

 https://www.escpweb.org/sites/escp/files/page_document/ESCP_Heidelberg_2017_All_Accepted_Abstracts_Update_11Sep2017.pdf

 157. Laven A, Deters MA, Rose O, Schwender H, Smaranda A, Waltering I, Laeer S. PHARMADHERE Study - How to train community pharmacists to provide efficient pharmaceutical care interventions to foster adherence. 46th European Society of Clinical Pharmacy Symposium on Clinical Pharmacy (ESCP), Heidelberg (October 2017)

156. Makowski N, Castro Diez C, Dalinghaus M, DeWildt S, Van der Meulen M, Bajcetic M, Jovanovic I, Male C, Ablonczy L, Szatmári A, Schwender H, Läer S. Standard of care for children with heart failure in Europe: Results of a survey and a subsequent Delphi questionnaire. 16th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Leuven (June 2017)

155. Burckhardt BB, Ciplea AM, Kleine K, Ablonczy L, Breur JMPJ, Dalinghaus M, van der Meulen M, Klingmann I, Spatenkova L, Swoboda V, NN Serbien, Keatley-Clark A, Laeer S, Lagler F. Novel tailored training concept to facilitate successful study conduct and optimize recruitment in paediatric clinical trials. 16th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Leuven (June 2017)

154. Deters MA, Läer S, Obarcanin E. Transition instead of transfer for drug treatment in adolescent diabetes type 1. ESDPPP, Leuven, Belgium, Abstracts p. 22, Poster PP-8

http://esdppp.org/site/wp-content/uploads/2017/10/Archdischild-2017-esdppp.pdf

2016

153. Burckhardt BB, Ciplea AM, Laven A, Klingmann I, Laeer S, Lagler F. A novel simulation-based approach to train study teams for clinical trials in neonates, infants and children with heart failure. 50th Annual Meeting of the Association for European Paediatric and Congenital Cardiology, 2016, Rome (I)

152. Deters MA, Obarcanin E, Läer S. Pharmaceutical care provided by community pharmacists for adolescents with type 1 diabetes mellitus - follow-up of DIADEMA. DPhG Jahrestagung 2016, München, Tagungsband (2016), POS. 81, p. 118

https://www.dphg.de/fileadmin/downloads/DPhG2016_ConferenceBook_final.pdf

151. Rasool MF, Khalil F, Läer S.Optimizing clinical use of carvedilol in liver cirrhosis - a physiologically based pharmacokinetic approach. 5th Pharmacometrics in NRW, 2016, Bonn.

2015

150. Rasool MF, Khalil F, Läer S. A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients, 6th Annual Simcyp Virtual Seminar on Applications of Population-based IVIVE and PBPK (16th November, 2015).

149. Khalil F, Läer S. Bedeutung des „Off Label Gebrauchs“ in der Pädiatrie: Ist off Label auch Off Knowledge? vfa/Kindernetzwerk-Veranstaltung “Licht am Horizon”, Frankfurt, Germany (Oktober 2015)

148. Khalil F. Physiologically based pharmacokinetic modelling in children. 14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Rotterdam, Netherlands (October 2015)

147. Schaefer C, Cawello W, Andreas J-O. High predictability of plasma lacosamide and no differences by different age and gender through normalization processes. DPhG Annual Meeting, Düsseldorf (September 2015)

146. Rasool MF, Khalil F, Läer S. Investigation of altered organ blood flow on carvedilol disposition in adult and pediatric chronic heart failure patients by using PBPK modelling. DPhG Annual Meeting, Düsseldorf (September 2015)

145. Ciplea AM, Kleine K, Burckhardt BB, Läer S, Breitkreutz J, Špatenková L, Klingmann I. Implementation of a GxP compliant quality system encompassing all consortium members of the FP-7 funded LENA Project. DPhG Annual Meeting, Düsseldorf (September 2015)

144. Schaefer J, Burckhardt BB, Tins J, Laeer S. Child-appropriate high throughput HPLC-MS/MS for enalapril and enalaprilat in small sample volumes of serum and urine within a GCLP-compliant environment. DPhG Annual Meeting, Düsseldorf (September 2015)

143. Makowski N, Castro Diéz C, Khalil F, Läer S. Reliability and validity of an European survey on the pharmacological management of paediatric heart failure. DPhG Annual Meeting, Düsseldorf (September 2015)

142. Burckhardt BB, Tins J, Läer S. Evaluation of a regulatory-compliant bioanalytical setting suitable to determine pharmacokinetics and pharmacodynamics of enalapril in Phase II/III studies in all paediatric age groups. DPhG Annual Meeting, Düsseldorf (September 2015)

141. Rasool MF, Khalil F, Läer S. Physiologically based pharmacokinetic models for adult and paediatric chronic heart failure patients using the example of carvedilol treated patients. 15th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade (June 2015)

140. Obarcanin E, Läer S. Pharmaceutical care of adolescents with T1DM, DIADEMA Study; European Society for Developmental, Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade, Serbia (June 2015)

139. Ciplea AM, Kleine K, Burckhardt BB, Läer S, Breitkreutz J, Špatenková L, Klingmann I. Development and establishment of a quality-framework for the LENA project. 15th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade (June 2015)

138. Schaefer J, Burckhardt BB, Tins J, Laeer S. Child-appropriate high throughput HPLC-MS/MS for enalapril and enalaprilat in small sample volumes of serum and urine within a GCLP-compliant environment. 15th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade (June 2015)

137. Castro Díez C, Khalil F, Dalinghaus M, van der Meulen M, de Wildt S, Jovanovic I, Bajcetic M, Burch M, Male C, Klingmann I, Szatmári A, Ablonczy L, Schwender H, Läer S.. Design of a European survey on the pharmacological management of paediatric heart failure. 15th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade (June 2015)

136. Burckhardt BB, Tins J, Läer S. Innovative regulatory-conforming bioanalytical approaches enabling systematic investigations of pharmacokinetics and pharmacodynamics by paediatric clinical studies in all age groups. 15th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (ESDPPP), Belgrade (June 2015)

135. Rasool MF, Khalil F, Läer S. A PBPK approach for predicting carvedilol exposure in chronic heart failure. National meeting for pharmacometerics. “Pharmacometrics in NRW” 4th meeting, Münster, Germany 2015

2014

134. Obarcanin E, Krüger M, Läer S. Pharmaceutical care of adolescents with T1DM, DIADEMA study. German Diabetes Society (DDG) 49th Annual Symposium, Berlin, Germany (2014)

133. Obarcanin E, Krüger M, Läer S. Medikationsmanagement in Apotheken am Beispiel von Jugendlichen mit Diabetes Typ 1 (DIADEMA), DPhG Vortrag, Düsseldorf (2014)

132. Schaefer C, Cawello W, Andreas J-O. High Predictability of Plasma Lacosamide and No Relevant Differences by Age and Gender Following Normalization (P4.261) Seattle, USA (2014)

131. Schaefer C, Cawello W, Andreas J-O. Immediate Steady-state Concentration in Plasma after Oral or Intravenous Lacosamide Loading Dose (P4.263) Seattle, USA (2014)

130. Laven A, Schaefer J, Laeer S. PHARMAGRIPS: Structured pharmaceutical counseling in the self-medication of the common cold. A randomised controlled study (RCT). FIP Annual Meeting, Bangkok. 2014

129. Khalil F., Läer S. Physiologically based pharmacokinetic Models in the prediction of oral Drug exposure over the entire pediatric age range-sotalol as a model drug. Simcyp Virtual Seminar (November 2014)

128. Khalil F, Läer S. WP 5: Modeling and Simulation- Top line PK-result of WP07 and implications for WP08-WP10. LENA General Assembly Meeting, Salzburg, Austria (October 2014)

127. Khalil F. Application of paediatric PBPK models in drug development and research for ivabradine and amiodarone. National meeting for pharmacometrics: „Pharmacometrics in NRW” 3rd Meeting. Düsseldorf, Germany (July 2014)

126. Rasool MF, Khalil F, Läer S. A PBPK model for assessing impact of reduced organ blood flows on carvedilol exposure in heart failure. National meeting for pharmacometerics. “Pharmacometrics in NRW” 3rd meeting; 2014 Düsseldorf, Germany (July 2014)

2013

125. Khalil F, Läer S. A bottom-up approach to simulate amiodarone pharmacokinetics in children. National meeting for pharmacometrics: „Pharmacometrics in NRW” 2nd Meeting, Cologne, Germany (2013)

124. Khalil F, Läer S. Physiologically based pharmacokinetic models to describe oral sotalol exposure from adults to children. A comparison of two modeling software. National meeting for pharmacometrics: „Pharmacometrics in NRW” 1st Meeting, Cologne, Germany (2013)

123. Burckhardt BB, Ramusovic S, Tins J, Läer S „Tailored bioanalytical methods for determination of aliskiren, enalapril and enalaprilat in serum and urine for systematic pharmacokinetic investigations in paediatric patients”, ESDPPP. Salzburg. 2013

122. Laven A, Laeer S. Evidenzbasierte Leitlinien für die Selbstmedikation: Anforderungen der Pharmazeuten für den Apothekenalltag. Jahrestagung des Deutschen Netzwerks für Evidenzbasierte Medizin. Berlin. 2013

121. Ehlers B, Läer S. Computerized physician order entry and clinical decision support systems in pediatrics – a literature overview. 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology. Salzburg. 2013

120. Lüpken R, Läer S. Requirements for a physiologically based pharmacokinetic model of tacrolimus in adults. 14th ESDP Congress in Salzburg (2013)

119. Lüpken R, Läer S. Tacrolimus pharmacokinetics in transplanted patients: Role of pharmacogenetics background of patients 2nd Pharmacometrics Platform in Köln (2013)

118. Lüpken R, Läer S. Requirements for a physiologically based pharmacokinetic model of tacrolimus in adults. 14th ESDP Congress in Salzburg (2013)

117. Rasool F, S. Läer. Physiologically based pharmacokinetic modeling of carvedilol. Pharmacometrics in NRW, Cologne, Germany (2013)

116. Rasool F, S. Läer. Approaches for Physiologically based pharmacokinetic modeling of carvedilol. 14th ESDPPP Congress, Salzburg, Austria (2013) 

2012

115. Khalil F, Läer S. Assembling of a multicenter and multinational data base to develop and validate a physiologically based pharmacokinetic sotalol model for pediatric extrapolation. Annual Meeting in National Harbor, Maryland (2012).

2011

114. Burckhardt BB, Ramusovic S, Jaffan L, Läer S „Identification of children at risk for high blood pressure out of routine blood pressure monitoring data„ auf der Jahrestagung der ÖPhG und DPhG in Innsbruck (2011)

113. Lüpken R, Läer S. FDA labled biomarkers in the personalized medicine of drug prescriptions on a pediatric ward. ÖPhG- und DPhG-Jahrestagung, Innsbruck (2011)

112. Schunk C, Heiter D, Lüpken R, Läer S. Self-medication in Germany: The new role of pharmacists to contribute to pharmacovigilance. ÖPhG- und DPhG-Jahrestagung in Innsbruck (2011).

111. Khalil F, Läer S. Physiologically-based pharmacokinetic modeling as a tool to explore drug disposition in newborns and infants and point to a new area of research. 13th ESDPPP Congress, Oslo, Norway (2011).

110. Khalil F, Läer S. Physiology-based pharmacokinetic modeling as a tool to explore drug disposition in pediatrics and point to a new area of research. Clinical Trials in pediatrics 7th edition, Genoa, Italy (2011).

109. Jaffan L, Gorny M, Läer S. High susceptibility for prescribing errors of pro re nata (on demand) medication jeopardize children's medication safety in a hospital setting. ÖPhG- und DPhG-Jahrestagung in Innsbruck (2011).

108. Müller SM, Jaffan L, Kloiber E, Läer S. Dextromethorphan use and abuse in German adolescents: Do we need to change its market access? ÖPhG- und DPhG-Jahrestagung in Innsbruck (2011).

107. Schunk C, Heiter D, Lüpken R, Läer S. Self-medication in Germany: The new role of pharmacists to contribute to pharmacovigilance. ÖPhG- und DPhG-Jahrestagung in Innsbruck (2011).

106. Lüpken R, Läer S. FDA labled biomarkers in the personalized medicine of drug prescriptions on a pediatric ward. ÖPhG- und DPhG-Jahrestagung in Innsbruck (2011).

105. Burckhardt BB, Ramusovic S, Jaffan L, Läer S. Identification of children at risk for high blood pressure out of routine blood pressure monitoring data. ÖPhG- und DPhG-Jahrestagung in Innsbruck (2011).

104. Gorny M, Jaffan L, Läer S.  “KinderDosierung”, a Clinical Decision Support System for children: A novel tool to increase medication safety. 13th ESDPPP Congress, Oslo, Norway (2011).

2010

103. Khalil F, Ramusovic S, Läer S. Paediatric drug trials and clinical practice- challenges for clinical pharmacists. 2nd Expert Workshop "Can the "in silico Child" help to develop better medicines for our children", Genua, Italy (2010).

102. Jaffan L, Gorny M, Läer S. Medication errors in pediatric inpatients: Identification and prevention by a clinical pharmacist. DPhG-Tagung in Braunschweig (2010). 

101. Läer S. Pediatric Drug Development and Future Directions. (oral presentation at the "American Heart Association, Scientific Sessions 2010", Chicago).  Session 3012 (2010). 

100. Ramusovic S, Frobel A-K, Läer S. Physiology Based Modeling to Support Pediatric Cardiovascular Drug Research - Potential Applications Using Amiodarone and Enalapril as Examples. (oral presentation at the "American Heart Association, Scientific Sessions 2010", Chicago). Circulation 122, A19468 (2010). 

99. Frobel A-K, Ramusovic S, Läer S. Physiologically - Based Pharmacokinetic (PBPK) Moddeling of Bisoprolol in Adults and Children and External Model Validation in a Paediatric Clinical Trial. 19th annual meeting of the Population Approach Group in Europe, Berlin, Germany. ISSN 1871-6032. PAGE 19 Abstr 1780 (2010).

98. Ramusovic S, Willmann S, Läer S. System biology for drug therapy - a mechanistic physiology based model of the interaction between enalapril and the Raa-System. 2010, Atlanta, USA; Clin Pharmacol Ther  87: S9-S37 (2010).

97. Ramusovic S, Frobel AK, Willmann S, Läer S. An intergrated whole-body physiology based pharmacokinetic / pharmacodynamic model of enalapril and the RAA - system. 19th annual meeting of the Population Approach Group in Europe, Berlin, Germany. ISSN 1871-6023. PAGE 19 Abstr 1865 (2010).

96. Gorny M, Jaffan L, Läer S. Dosage Recommendations for Children: "Kinder Dosierung", a Web Based Clinical Decision Support System for Children. 3. Deutscher Kongress für Patientensicherheit bei medikamentöser Therapie, Berlin, Deutschland (2010).

95. Jaffan L, Gorny M, Läer S. Identification and prevention of mediication errors by a clinical pharmacist on a pediatric ward. 3. Deutscher Kongress für Patientensicherheit bei medikamentöser Therapie, Berlin, Deutschland (2010).

2009

94. Ramusovic S, Willmann S, Läer S. A physiologically based pharmacodynamic model of the Renin-Angiotensin-Aldosterone-System. Annual Meeting of the Population Approach Group Europe (PAGE) St.Petersburg, Russia (2009). 

93. Vogt W, Läer S. European survey on the pharmacological management of low cardiac output syndrome in children undergoing cardiac surgery with cardiopulmonary bypass (EuLoCOS-Paed). In Proceedings of the 12th ESDPPP Congress, Chamonix, France (2009).

92. Ramusovic S, Läer S. A physiologically based pharmacodynamic model of the Renin-Angiotensin-Aldosterone-System. In Proceedings of the 12th ESDPPP Congress, Chamonix, France (2009).

91. Khalil F, Läer S. Development of a physiologically based pharmacokinetic model for a typical “kidney drug” -Sotalol- in adults and children. In Proceedings of the 12th ESDPPP Congress, Chamonix, France (2009).

90. Jaffan L, Vogt W, Läer S. Drug-related problems on paediatric wards: Proposing a “PCNE for children” for hospital quality management in paediatric pharmacotherapy. In Proceedings of the 12th ESDPPP Congress, Chamonix, France (2009).

89. Gorny M, Läer S. Dosage Recommendations for Children: Developing a Clinical Decision Support System for Pediatrics. In Proceedings of the 12th ESDPPP Congress, Chamonix, France (2009). 

88. Frobel A-K, Läer S. Physiology-based pharmacokinetic simulation of bisoprolol as a rationale for dosing in future paediatric clinical trials (oral presentation). In Proceedings of the 12th ESDPPP Congress, Chamonix, France (2009). 

87. Schmidt D, Läer S. Discrimination of serotonin transporter polymorphism genotypes using real time PCR. Basic Clin Pharmacol Toxicol, 104, 501 (2009).

86. Frobel A-K, Läer S. Physiology-based simulations help to find bisoprolol as a rational drug of choice for a randomisedcontrolled trial in children with congestive heart failure. 75. Jahrestagung der Deutschen Gesellschaft für Kardiologie in Mannheim, Vortrag V72 (2009).

85. Hsien L, Vogt W, Läer S. Simulation of sildenafil disposition in virtual children by means of a physiologically based pharmacokinetics modelling. Naunyn Schmiedebergs Arch Pharmacol, 379 Supplement 1, 4798 (2009).

84. Gorny M, Läer S. A clinical decision support system for paediatrics: progress of development. Naunyn Schmiedebergs Arch Pharmacol, 379 Supplement 1, 497 (2009).

83. Frobel A-K, Läer S. Identifying bisoprolol as the beta-blocker of choice for a clinical trial in children with congestive heart failure using physiology-based pharmacokinetic simulation. Naunyn Schmiedebergs Arch Pharmacol, 379 Supplement 1, 496 (2009).

82. Breddemann A, Laws J, Bührmann S, Dohna-Schwake C, Tot E, Läer S. Validation of physiologically-based simulations for cidofovir pharmacokinetics in critically ill paediatric patients. Naunyn Schmiedebergs Arch Pharmacol, 379 Supplement 1, 495 (2009).

81. Schmidt D, Läer S. Discrimination of serotonin transporter polymorphism genotypes using real time PCR. Naunyn Schmiedebergs Arch Pharmacol, 379 Supplement 1, 473 (2009).

2008

80. Vogt W, Frobel A-K, Ramusovic S, Laer S. The in silico child helps to design paediatric dosing regimens a priori: an example with Milrinone. Clin Res Cardiol. 97:707 (2008).

79. Frobel AK, Schmidt KG, Hulpke-Wette M, Läer S. Evidence for the use of beta-adrenoceptor-blockers in paediatric congestive heart failure. A Cochrane Review. Abstractband der Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Posterbeitrag B69 (2008).

78. Breddemann A, Laws J, Bührmann S, Tot E, Läer S. Physiologically-based pharmacokinetic modelling and clinical pharmacokinetics of cidofovir in paediatric patients. Abstractband der Jahrestagung der Deutschen Pharmazeutischen Gesellschaft Vortrag K33 (2008).

77. Gorny, M. Jaffan L, Läer, S. Development of a clinical decision support system for children.  Abstractband der Jahrestagung der Deutschen Pharmazeutischen Gesellschaft Posterbeitrag B70 (2008).

76. Schmidt D, Läer S. Discrimination of serotonin transporter polymorphism genotypes using real time PCR. 10. Jahreskongress für Klinische Pharmakologie, Berlin (2008).

75. Nir A, Lindberger A, Rauh M, Bar-Oz B, Läer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS. Normal values, range and upper limits, of Nt-pro-B-type natriuretic peptide in infants and children. Analysis and combined from 4 studies. Cardiology in the Young 18, Supplement 1, 40 (2008).

74. Ramusovic S, Vogt W, Läer S. Simulation of a virtual paediatric population as a basis for an amiodarone dosing regimen. Cardiology in the Young 18, Supplement 1, 40 (2008).

73. Hsien L, Breddemann A, Frobel A-K, Heusch A, Schmidt K G, Läer S. Off-label drug use among hospitalised children: Identifying areas with the highest need for research. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children, Rotterdam, Netherlands, pp.115 (2008).

72. Breddemann A, Laws J, Bührmann S, Tot E, Läer S. Combination of physiologically-based pharmacokinetic simulations with detection of paediatric cidofovir pharmacokinetics: Rationale of a multi centre clinical trial. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children, Rotterdam, Netherlands, pp.37 (2008).

71. Frobel A-K, Ramusovic S, Vogt W, Läer S. Simulation of metoprolol plasma concentracion profiles in children using a physiologically based pharmacokinetic model as a basis for paediatric dosing recommendations. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children, Rotterdam, Netherlands, pp.73 (2008).

70. Vogt W, Ramusovic S, Frobel A-K, Laer S. Evaluation of a physiologically based pharmacokinetic model of milrinone for children undergoing cardiac surgery. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children, Rotterdam, Netherlands, pp.94 (2008).

69. Ramusovic S, Vogt W, Frobel A-K., Laer S. Physiologically based modelling for the development of a paediatric dose regimen for oral long-term therapy with amiodarone.  In Proceedings of the 11th ESDP Congress Safe and effective medicines for children,  Rotterdam, Netherlands, pp.90 (2008).

2007

68. Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt K, Läer S. High rate of off-label use in cardiovascular paediatric pharmacotherapy requires new focus in research.  Naunyn Schmiedebergs Arch Pharmacol, 375 Supplement, R 564 (2007).

67. Breddemann A, Läer S, Schmidt KG, Harjes M, Adam R,  Ludwig A, Niehues T, Schneider DT. Case Report: Severe gastrointestinal inflammation related to persistent HHV-6B infection in a 10-month old cancer patient. Naunyn Schmiedebergs Arch Pharmacol, 375 Supplement, R 563 (2007).

66. Röhm S, Frobel AK, Tot E, Läer S. Actual necessity of predictive CYP2D6-gendiagnostics in psychiatric therapy. Naunyn Schmiedebergs Arch Pharmacol, 375 Supplement, R 537 (2007).

2006

65. Verde PE, Albers S, Läer S. Statistical analysis and confidence intervals for the maximum oxygen uptake for a subject: a modern statistical approach. ISCB Annual Conference 2006.

2005

64. Läer S, JP.Elshoff, Meibohm B, Weil J, Mir TS, Zhang W, Hulpke-Wette M.Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol using clinical trial simulation and population pharmacokinetics. Z Kardiol 94, Suppl 1 (2005). 

63. Läer S, Albers S, Gupta M, Mir TS, Meibohm B Population pharmacokinetics of carvedilol in pediatric patients with congestive heart failure. Clin Pharmacol Ther 73, PII-144, P88 (2005). 

2004

62. Albers S, Mir TS, Falkenberg J, Haddad M, Budden R, Weil J, Läer S. valuation of NBNP for Pediatric Patients in Multicenter Studies. Z Kardiol 93; 739 (2004). 

61. Albers S, Mir TS, Falkenberg J. Flato M, Haddad M, Budden R, Weil J, Läer S. Evaluation of the cardiac biomarker Nt-pro BNP in children to guide harmacotherapy. ESDP Meeting (2004). 9th Biennal Congress, p 114.

60. Läer S, Elshoff JP, eibohm B, Weil J, Mir TS, Hulpke-Wette M. Development of a Pediatric Dosing Regimen for Sotalol. ESDP Meeting (2004). 9th Biennal Congress, p 72. 

59. Mir TS,Flato M, Falkenberg J,Haddad M, Budden R, Weil J, Albers S, Läer S. Plasma concentrations of N-terminal brain natriuretic peptide (n-bnp) in healthy children and adolescents: reference values and effect of age and gender. Z Kardiol 93, Suppl 3 (2004). 

58. Kindermann M, Maack C, Schaller S, Finkler N, Läer S, Wuttke H, Böhm M. Atypisch hohe Affinität von Carvedilol, aber nicht Metoprolol, zu humanen β-Adrenozeptoren bewirkt prolongierte β-adrenerge Inhibition auch nach kompletter Plasma-Elimination. Z Kardiol 93, Suppl 3 (2004). 

2003

57. Kindermann M, Maack C, Schaller S, Finkler N, Läer S, Wuttke H, Böhm M. Atypical binding of carvedilol to betaadrenoceptors prevents betareceptor rebound phenomen. Circulation 108, Supplement, IV-465 (2003). 

56. Läer S, Elshoff JP, Mir TS, Hulpke-Wette M, Weil J. Body weight and age for individually adjusted a priori sotalol dosing in children with supraventricular achycardia. Circulation 108, Supplement, IV-370 (2003). 

55. Läer S, Elshoff JP. Microdialysis as a new blood free method to determine plasma drug levels in pediatric patients. Z Kardiol 92, I/183-184 (2003). 

54. Läer S, Elshoff JP, Mir TS, Müller-Wolf C, Weil J, Hulpke-Wette M, Meibohm B. Dosing rationale using population pharmacokinetics of sotalol in children with tachycardia. Naunyn Schmiedebergs Arch Pharmacol, 367 Supplement, R 114 (2003). 

53. Meibohm B, Zhang W, Elshoff JP, Behn F, Hulpke-Wette M, Läer S. Population pharmacokinetics and pharmacodynamics of sotalol in infants and children with tachycardia. Clin Pharmacol Ther 73, PIII-37, 71 (2003). 

2002

52. Läer S, Elshoff JP, Zhang W, Meibohm B. Population pharmacokinetic modeling for sotalol in pediatric patients with tachycardia. Eur J Clin Pharmacol 58, S76 (2002). 

51. Mir TS, Marohn S, Eiselt M, Haun C, Läer S, Laux R, Weil J. Plasma Concentrations of N-Terminal Brain Natriuretic Peptide (N-BNP) in healthy children and in children with heart diseases. Circulation, im Druck (2002). 

50. Mir TS, Marohn S, Läer S, Eiselt M, Haun C, Hellwege HH, Laux R, Weil J. Nt-pro-brain natriuretic peptide (N-BNP) zur Diagnostik, Risikostratifizierung und Therapiesteuerung bei Kindern mit angeborenen und erworbenen Herzerkrankungen. Kongreß im Rahmen der 51. Jahrestagung der Norddeutschen Gesellschaft für Kinderheilkunde und Jugendmedizin, Hamburg, 26.-28. April (2002). 

49. Läer S, Behn F, Meibohm B. Developmental pharmacodynamics of carvedilol in pediatric patients with congestive heart failure. 4th International Symposium: Advances in simultaneous pharmacokinetic/pharmacodynamic modelling, 24-27 April, (2002), Noordwijkerhout, Niederlande 

48. Kirchhoff P, Degen L, Fabritz L, Läer S, Neumann J, Haverkamp. Post-repolarization refractoriness and flattened restitution - a novel explanation for the antiarrhythmic efficacy of amiodarone. Naunyn Schmiedebergs Arch Pharmacol, 365 Supplement, R 110 (2002). 

47. Behn F, Scholz H, Läer S. Different development of the pharmacokinetics of R- and Scarvedilol in children with heart failure. Naunyn Schmiedebergs Arch Pharmacol, 365 Supplement, R 110 (2002). 

46. Elshoff JP, Scholz H, Läer S. Microdialysis as a tool for pharmacokinetic studies in special populations - experiments with sotalol. Naunyn Schmiedebergs Arch Pharmacol, 365 Supplement, R 109 (2002). 

2001

45. Behn F, Läer S, Scholz H, Mir TS, Weil J, Meibohm B. Enantiospecific PK/PD-modeling of heart rate and mean arterial pressure during carvedilol treatment in children with congestive heart failure. ESDP Congress, Abstract p22, Limassol/Zypern, 17-20 November (2001). 

44. Läer S, Elshoff JP, Scholz H, Wauer I, Meibohm B, Mir TS, Weil J, Hulpke-Wette M. Developmental changes in proarrhythmic and antiarrhythmic action of sotalol in children with tachycardia. Circulation 104, Supplement II, II-488/489 (2001). 

43. Läer S, Behn F, Scholz H, Eiselt M, Mir TS, Weil J, Meibohm B. Successful therapy with carvedilol in pediatric patients with myocardial failure. Circulation 104, Supplement II, II- 679, (2001). 

42. Behn F, Eiselt M, Läer S, Mir TS, Scholz H, Weil J. Effects of the beta-adrenoceptor blocker carvedilol in children with myocardial failure. XXXIV International Congress of Physiological Sciences, Abstract Nr. 26, Christchurch/New Zealand, 26-31 August (2001).

41. Läer S, Behn F, Elshoff JP, Scholz H, Wauer I, Hulpke-Wette M, Meibohm B, Mir TS, Weil J. Drug response in pediatric patients with heart disease. Naunyn Schmiedebergs Arch Pharmacol, 363 Supplement, R 117 (2001). 

40. Läer S, Wauer I, Elshoff JP, Meibohm B, Scholz H, Mir TS, Weil J, Hulpke-Wette M. Effects of sotalol in pediatric patients: evidence for developmental changes in sotalol´s proarrhythmic and antiarrhythmic action. Z Kardiol 90, II/55 (2001). 

39. Läer S, Behn F, Scholz H, Mir TS, Weil J, Meibohm B. Carvedilol for pediatric congestive heart failure: do young children behave like little adults? Clin Pharmacol Ther 69, PII-79, 52 (2001). 

2000

38. Elshoff JP, Läer S, Wauer I, Behn F, Scholz H. Microdialysis in venous blood samples adding a colloid to the perfusion fluid - an in vitro study. Eur J Clin Pharmacol 56, A 24 (2000). 

37. Wauer I, Läer S, Behn F, Scholz H, Hulpke-Wette M, Mir TS, Weil J, Meibohm B. Sotalol in pediatric patients with supraventricular tachycardia: dosage regimens based on body weight or on body surface area? Eur J Clin Pharmacol 56, A 18 (2000). 

36. Mir TS, Mahron S, Eiselt M, Läer S, Scholz H, Weil J. Effect of carvedilol on heart rate corrected QT-interval and QT dispersion in pediatric patients with congestive heart failure. Eur Heart J, Supplement 21, 436 (2000). 

35. Mir TS, Eiselt M, Marohn S, Läer S, Behn F, Scholz H, Weil J. Treatment of congestive heart failure with betareceptorblockers on pediatric patients. Eur Heart J, Supplement 21, 432 (2000). 

34. Behn F, Läer S, Scholz H, Mir TS, Weil J, Meibohm B. Heart rate and mean arterial pressure during carvedilol therapy in children of different ages. Naunyn Schmiedebergs Arch Pharmacol, Supplement 361, R 123 (2000). 

33. Läer S, Behn F, Wauer I, Hulpke-Wette M, Mir TS, Meibohm B. Pharmacokinetics of sotalol in children with supraventricular tachycardia. Clin Pharmacol Ther 67, PII-63, 130 (2000). 

1999

32. Läer S, Behn F, Scholz H, Mir TS, Eiselt M, Weil J. Differences in carvedilol pharmacokinetics between children and adults. Z Kardiol 88, 758 (1999).

31. Mir TS, Eiselt M, Banhidai M, Läer S, Behn F, Scholz H, Weil J. Therapie der chronischen Herzinsuffizienz mit ß-Rezeptorblockern bei pädiatrischen Patienten am Beispiel von Carvedilol. Z Kardiol 88, 758 (1999).

30. Ritterbach C, Scholz J, Läer S, Schulte am Esch J. Ein erhöhter Serotoninumsatz unter Allgemeinanaesthesie korreliert mit postoperativer Übelkeit und Erbrechen. Anaesthesiol Intensivmed Notfallmed Schmerzther 40, 337 (1999). 

29. Läer S, Behn F, Scholz H, Mir TS, Eiselt M, Venzke A, Weil J, Meibohm B. Carvedilol in children with congestive heart failure. Eur J Clin Pharmacol 55, A30 (1999). 

28. Mir TS, Eiselt M, Läer S, Behn F, Venzke A, Scholz H, Weil J. Erweiterte Therapie der Herzinsuffizienz bei pädiatrischen Patienten mit dem ß-Rezeptorenblocker Carvedilol. Z Kardiol 88, 216 (1999). 

27. Läer S, Behn F, Scholz H, Mir TS, Eiselt M, Venske A, Weil J. Carvedilol therapy in infants - dose adjustment due to genetic polymorphism of cytochrome P450 2D6. Z Kardiol 88, 216 (1999). 

26. Läer S, Scholz H, Stein B, Uebeler J, Tsilimingas N, Boknik P, Neumann J. Regional expression of 5-HT4 splice variants splice variants in the human heart. Naunyn Schmiedebergs Arch Pharmacol, Supplement 359, R 105 (1999). 

25. Arndt J, Läer S, Liebau M, Scholz H, Warnholtz A, Meinertz T.Low dose amiodarone treatment - pharmacodynamic and pharmacokinetic parameters. Naunyn Schmiedebergs Arch Pharmacol, Supplement 359, R 127 (1999). 

24. Behn F, Läer S, Scholz H, Mir TS, Eiselt M, Venske A, Weil J, Meibohm B. Carvedilol in children with congestive heart failure - pharmacokinetic parameters. Naunyn Schmiedebergs Arch Pharmacol, Supplement 359, R 130 (1999). 

1998

23. Mir TS, Eiselt M, Fenske A, Läer S, Behn F, Scholz H, Weil J. Erste klinische Erfahrungen mit dem ß-Rezeptorenblocker Carvedilol zur Behandlung der Herzinsuffizienz bei Kindern. Z Kardiol 87, 770 (1998). 

22. Behn F, Läer S, Mir TS, Scholz H, Weil J. Age related sotalol pharmacokinetics require modified dosage regimens in infants. Eur J Clin Pharmacol 54, A7 (1998). 

21. Läer S, Neumann J, Remmers F, Scholz H. Comparison of functional coupling and mRNA expression of 5-hydroxytryptamine receptor subtypes in human and rat heart. Naunyn Schmiedebergs Arch Pharmacol, Supplement 358, R 632 (1998). 

20. Läer S, Remmers F, Scholz H, Ismail M, Neumann J. Signal transduction of 5-hydroxytryptamine receptors in human and rat atrium. Z Kardiol 87, 279 (1998). 

19. Remmers F, Läer S, Scholz H, Ismail M, Neumann J. Differences between functional coupling and mRNA expression of 5-hydroxytryptamine receptor subtypes in human and rat atrium. Naunyn Schmiedebergs Arch Pharmacol, Supplement 357, R 393 (1998). 

1997

18. Läer S, Scholz H, Ritterbach C, Scholz J. Increased serotonin turnover in patients undergoing surgery with general anaesthesia. Naunyn Schmiedebergs Arch Pharmacol, Supplement 356, R 53 (1997). 

17. Läer S, Scholz H, Buschmann I, Thoenes M, Meinertz T. Evidence for a new drug interaction: digitoxin toxicity after amiodarone co-treatment. Eur J Clin Pharmacol 52, A7 (1997). 

16. Läer S, Scholz H, Uebeler P, Neumann J. Charakterisierung von Inotropie und Chronotropie am Rattenherzen. Z Kardiol 86, R 1237 (1997). 

15. Läer S, Apel M, Scholz H, Boknik P, Neumann J. Chronic adrenergic stimulation leads to alterations in serotonin metabolism and cardiac mRNA expression of 5-HT subreceptors in rat. Naunyn Schmiedebergs Arch Pharmacol, Supplement 355, R 355 (1997). 

14. Liebau M, Läer S, Scholz H, Neumann J. Interaction between D,L-sotalol and the cholesterol lowering drug colestyramine. Naunyn Schmiedebergs Arch Pharmacol, Supplement 355, R 450 (1997). 

1996

13. Läer S, Scholz H, Neumann J, Gams E, Zimmermann N. Amiodarone, sotalol and diltiazem levels in human cardiac tissues. Relations to peroral dosages and blood levels. Acta Physiologica Pharmacologica et Therapeutica Latinoamericana, 144 (1996). 

12. Läer S, Scholz H, Neumann J, Gams E, Zimmermann N. Diltiazem levels in human cardiac tissues. Relation to peroral dosage and blood levels. Naunyn Schmiedebergs Arch Pharmacol, Supplement 353, R 154 (1996). 

11. Läer S, Scholz H, Neumann J. Tropisetron sensitive 5-hydroxytryptamine subreceptor affects contractility in guinea pig atria. Naunyn Schmiedebergs Arch Pharmacol, Supplement 353, R 56 (1996). 

1995

10. Reymann A, Froeschle O, Schäfer A, Bräsen J, Woermann C, Läer S, Meyer Pannwitt W. Pilot study on a clinical assay contributing to diagnosis of multidrug resistance in gastrointestinal tumors. Anticancer Res 15 (6A), 2437-2438 (1995). 

9. Läer S, Neumann J, Scholz H. Pharmacodynamically relevant interaction between D,Lsotalol and an antacid preparation (MaaloxR). Circulation 8, Supplement I, I-194 (1995). 

8. Läer S, Neumann J, Scholz H. Interaction between D,L-sotalol and an antacid preparation (MaaloxR). Thérapie 4, Supplement 479 (1995). 

7. Läer S, Bunge A, Dietel M, Meyer Pannwitt U, Schaefer A, Trapp M, Woermann C, Reymann A. Human leukemia cell lines K562-RADR express low levels of p-glycoproteinmediated multidrug resistence: reference for clinical tumor specimen. Naunyn Schmiedebergs Arch Pharmacol, Supplement 351, R 20 (1995). 

1994

6. Läer S, Apel M, Bernhardt J, Kahl R. Bilirubin decreases superoxide anion radical concentration in human neutrophil granulocytes and xanthine oxidase system. Canadian J Physiol Pharmacol, Supplement 1, 519 (1994). 

5. Steinfath M, Scholz J, Reymann A, Läer S, Scholz H, Schulte Am Esch J.Ist das Plasmakonzentrationsprofil von Lidocain abhängig von der endobronchialen Medikamentenapplikation? Der Anaesthesist, Supplement 78, 24 (1994). 

4. Läer S, Apel M, Bernhardt J, Kahl R. Bilirubin decreases superoxide anion radical concentration in oxidase systems. Naunyn Schmiedebergs Arch Pharmacol, Supplement 349, R 119 (1994). 

1992

3. Läer S, Huether G, Block F, Sontag KH. Stimulation by carbachol of striatal dopamine release is dependent on the degree of prestimulation of opaminergic nerve terminals. Eur J Neuroscience, Supplement 5, 59 (1992). 

2. Läer S, Huether G, Block F, Sontag KH. Acute reduction of cerebral blood flow by clamping of both carotid arteries increases dopamin release. Abstracts of the 4th International Symposium on Pharmacology of Cerebral ischemia, Marburg, 31 (1992). 

1991

1. Läer S, Block F, Huether G, Reimer A, Sontag KH. Moderate reduction of cerebral blood flow induces changes in extracellular striatal dopamine and its metabolites; in: Synapse, Transmission, Modulation - Proc. 19th Göttingen Neurobiol. Conf.; Ed. Elsner N; Thieme Verlag, Stuttgart 1991, 375.

Institutsleiterin

Univ.-Prof. Dr. med. Stephanie Läer

Gebäude: 26.22.
Etage/Raum: 02.22
Tel.: +49 211 81-10740

Sekretariat

Claire Bunse

Gebäude: 26.22
Etage/Raum: 02.24
Tel.: +49 211 81-13664
Verantwortlich für den Inhalt: E-Mail sendenKlinische Pharmazie